H.C. Wainwright analyst Andrew Fein raised the firm’s price target on KalVista (KALV) to $37 from $27 and keeps a Buy rating on the shares. The firm believes the announced fiscal 2025 Ekterly revenue support the thesis that an oral therapy will become the on-demand therapy of choice for hereditary angioedema.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALV:
- KalVista price target raised to $29 from $28 at Citizens
- Strong Ekterly Launch and Latin America Expansion Underscore Buy Rating on KalVista
- KalVista Highlights Strong EKTERLY Launch and Global Uptake
- KalVista price target raised to $32 from $28 at Needham
- KalVista (Ekterly) Upgraded as 2026 Top Idea: De-Risked Competitive Landscape, Strengthening Launch Trajectory, and Raised $32 Target Support Buy Rating